PF-Atlas › Treatments › WNT/RSPO3 Agonist

WNT/RSPO3 Agonist

R-spondin 3 expands AEC2 stem cell pool via WNT pathway

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I IND
Evidence level
Level 3 (Phase I)
Mechanism class
R-spondin 3 expands AEC2 stem cell pool via WNT pathway
Timeline
3-5 years
Risk profile
Low-Medium
Developer
Entrega Bio / UCSF
Key researchers
H. Chapman

Overview

RSPO3 expands AEC2 organoids. WNT3a pathway drives AEC2 self-renewal. First drug to target the stem cell directly.

How WNT/RSPO3 Agonist fits into IPF treatment

WNT/RSPO3 Agonist is classified as Level 3 (Phase I) at the Phase I IND stage. Explore how it compares to other options and where it sits in the development pipeline:

WNT drug profileR-spondin 3 expands AEC2 stem cell pool via WNT pathwayClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about WNT/RSPO3 Agonist for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.